Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis

Stopped early · Phase 2/Phase 3

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to confirm the improvement in pulmonary function and cytokine levels observed in the recently completed multidose aerosol study for the treatment of Cystic Fibrosis (CF).

Key facts

Study ID

NCT00073463

Run by

Targeted Genetics Corporation

People needed

100

Starts

2003-06-01

Expected to finish

2005-10-01

Last updated by the study team

2008-01-28

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UAB-Childrens Health System — Birmingham, Alabama, United States
• Stanford University Medical Center — Palo Alto, California, United States
• UC San Diego — San Diego, California, United States
• University of Colorado-The Childrens Hospital — Denver, Colorado, United States
• University of Florida — Gainesville, Florida, United States
• The Johns Hopkins Hospital — Baltimore, Maryland, United States
• Mass General Hospital — Boston, Massachusetts, United States
• Childrens Hospital — Boston, Massachusetts, United States
• The Minnesota CF Center — Minneapolis, Minnesota, United States
• University of Nebraska — Omaha, Nebraska, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.